 |
|
Challenges to the Effective Use of Unfractionated Heparin in the Hospitalized Management of Acute Thrombosis
Elaine M. Hylek, MD, MPH;
Susan Regan, PhD;
Lori E. Henault, MPH;
Margaret Gardner, RN;
Andrew T. Chan, MD;
Daniel E. Singer, MD;
Michael J. Barry, MD
Arch Intern Med. 2003;163:621-627.
Background Unfractionated heparin therapy is care intensive because of dose-response variability, and because of the necessity of constant intravenous infusion and frequent monitoring. We sought to assess the real-world course of transition from heparin to warfarin in hospitalized patients undergoing anticoagulation therapy for acute venous or arterial thrombosis at our medical center.
Methods Patients were retrospectively identified from July 1998 to December 1998. Data collected included initiation and maintenance doses of heparin, frequency of monitoring and dose adjustments, time to the therapeutic range, complications and interruptions of therapy, and characteristics of heparin-to-warfarin transition.
Results Of the 311 patients who met the study criteria during the 6-month period, 134 had venous thromboembolism, 122 had cerebral arterial thrombosis, and 55 had peripheral arterial thrombosis. Groups differed in use and magnitude of initial heparin bolus, frequency of monitoring, and time to the therapeutic range. Dose response to intravenous heparin was highly variable. Even when the activated partial thromboplastin time reached the therapeutic range of 55 to 85 seconds, the next 2 consecutive measurements remained in this range in only 29% of the patients. Patients received an average of 4 different heparin doses over the first 3 days of treatment, and the therapeutic range was maintained on each of 4 sequential days in only 7% of them. During the course of therapy, 54% of the patients had at least 1 prolonged interruption in heparin infusion, and 4.8% sustained a major hemorrhage. Overall, 20% of the patients met the currently recommended treatment guideline of 4 days or more of heparin and warfarin overlap, until the international normalized ratio is greater than 2.0 for 2 consecutive days.
Conclusions Multiple challenges to effective anticoagulation treatment with unfractionated heparin exist in the hospital setting. Strategies are needed to improve the overall quality of anticoagulant care, including the substitution of low-molecular-weight heparin for unfractionated heparin, where appropriate.
From the Clinical Epidemiology Unit, General Medicine Division, Department of Medicine (Drs Hylek, Regan, Singer, and Barry, and Mss Henault and Gardner), and the Gastrointestinal Unit, Department of Medicine (Dr Chan), Massachusetts General Hospital and Harvard Medical School, Boston. Drs Hylek and Singer have received occasional honoraria for speaking engagements from DuPont Pharmaceuticals, now Bristol-Myers Squibb.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Racial Differences in 30-Day Mortality for Pulmonary Embolism
Ibrahim et al.
Am. J. Public Health 2006;96:2161-2164.
ABSTRACT
| FULL TEXT
Current and emerging treatment options for venous thrombosis: A case discussion
Haines and Nutescu
Am J Health Syst Pharm 2005;62:593-605.
FULL TEXT
Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism
McGuire and Dobesh
Journal of Pharmacy Practice 2004;17:289-307.
ABSTRACT
The Effect of Excessive Anticoagulation on Mortality and Morbidity in Hospitalized Patients With Anticoagulant-Related Major Hemorrhage
Koo et al.
Arch Intern Med 2004;164:1557-1560.
ABSTRACT
| FULL TEXT
Comment: venous thromboembolism prophylaxis conversion in nonsurgical inpatients
Fanikos and Tsilimingras
The Annals of Pharmacotherapy 2003;37:1914-1915.
FULL TEXT
|
